Open AccessTransplantation of human villous trophoblasts preserves cardiac function in mice with acute myocardial infarction
Author(s) -
Wang Zegen,
Dong Ningzheng,
Niu Yayan,
Zhang Zhiwei,
Zhang Ce,
Liu Meng,
Zhou Tiantian,
Wu Qingyu,
Cheng Ke
Publication year - 2017
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13165
Subject(s) - stem cell , mesenchymal stem cell , angiogenesis , medicine , transplantation , matrigel , embryonic stem cell , immunology , cancer research , microbiology and biotechnology , biology , pathology , gene , biochemistry
Over the past decade, cell therapies have provided promising strategies for the treatment of ischaemic cardiomyopathy. Particularly, the beneficial effects of stem cells, including bone marrow stem cells ( BMSC s), endothelial progenitor cells ( EPC s), mesenchymal stem cells ( MSC s), embryonic stem cells ( ESC s), and induced pluripotent stem cells ( iPSC s), have been demonstrated by substantial preclinical and clinical studies. Nevertheless stem cell therapy is not always safe and effective. Hence, there is an urgent need for alternative sources of cells to promote cardiac regeneration. Human villous trophoblasts ( HVT s) play key roles in embryonic implantation and placentation. In this study, we show that HVT s can promote tube formation of human umbilical vein endothelial cells ( HUVEC s) on Matrigel and enhance the resistance of neonatal rat cardiomyocytes ( NRCM s) to oxidative stress in vitro . Delivery of HVT s to ischaemic area of heart preserved cardiac function and reduced fibrosis in a mouse model of acute myocardial infarction ( AMI ). Histological analysis revealed that transplantation of HVT s promoted angiogenesis in AMI mouse hearts. In addition, our data indicate that HVT s exert their therapeutic benefit through paracrine mechanisms. Meanwhile, injection of HVT s to mouse hearts did not elicit severe immune response. Taken together, our study demonstrates HVT may be used as a source for cell therapy or a tool to study cell‐derived soluble factors for AMI treatment.